by jtcir-auto | Apr 11, 2022 | Press Releases
– Company to present regarding AIM Biologicals as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder (“NMOSD”), an orphan indication with strong unmet medical need TORONTO, ONTARIO, April 11, 2022 (GLOBE NEWSWIRE)...
by jtcir-auto | Apr 11, 2022 | Press Releases
– Company to present regarding AIM Biologicals as a potential therapeutic treatment option for neuromyelitis optica spectrum disorder (“NMOSD”), an orphan indication with strong unmet medical need TORONTO, ONTARIO, April 11, 2022 (GLOBE NEWSWIRE)...
by jtcir-auto | Mar 29, 2022 | Press Releases
– Continue to advance and expand opportunities with established diversified development pipeline – Company ended the year with $65.3 million in cash, expected to fund operations through 2023 TORONTO, ONTARIO, March 29, 2022 (GLOBE NEWSWIRE) — Aeterna...
by jtcir-auto | Mar 29, 2022 | Press Releases
– Continue to advance and expand opportunities with established diversified development pipeline – Company ended the year with $65.3 million in cash, expected to fund operations through 2023 TORONTO, ONTARIO, March 29, 2022 (GLOBE NEWSWIRE) — Aeterna...
by jtcir-auto | Mar 21, 2022 | Press Releases
– Company actively monitoring delays to mitigate potential impact of COVID-19 and conflict in Ukraine following Russian invasion on the estimated completion dates for the trial – Patient enrollment expected to continue into 2023 TORONTO, ONTARIO, March 21,...